Actively Recruiting

Age: 18Years - 75Years
All Genders
NCT05870969

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)

Led by Ruijin Hospital · Updated on 2023-05-23

20000

Participants Needed

1

Research Sites

261 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.

CONDITIONS

Official Title

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Voluntary participation with signed informed consent and ability to complete all study procedures
  • Age between 18 and 75 years old
  • Diagnosis of chronic hepatitis B with persistent positive hepatitis B surface antigen for 6 months or more
  • Diagnosis of chronic hepatitis C
  • Diagnosis of liver cirrhosis confirmed by biopsy, liver stiffness measurement, imaging, APRI score, or FIB-4 score
  • Diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD) with liver fibrosis score F3 or higher by transient elastography
  • MAFLD diagnosis requires >5% liver fat accumulation plus overweight/obesity, type 2 diabetes, or metabolic dysfunction
  • Diagnosis of MAFLD combined with abnormal glucose metabolism including type 2 diabetes, prediabetes, or elevated glycated hemoglobin
  • Family history of liver cancer in first-degree biological relatives
Not Eligible

You will not qualify if you...

  • Age under 18 years or over 75 years
  • Previous diagnosis of liver cancer
  • Severe mental illness or cognitive impairment
  • Pregnant, lactating, or planning pregnancy
  • Participation in other clinical trials within 3 months prior to study treatment
  • Judged by doctor as unable to understand study, poor compliance, infirmity, or other factors making the subject unsuitable for the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

Actively Recruiting

Loading map...

Research Team

Q

Qing Xie, MD

CONTACT

H

Honglian Gui, MD,PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH) | DecenTrialz